JPH0471484A - Low aggregating cell and method for culturing the same - Google Patents

Low aggregating cell and method for culturing the same

Info

Publication number
JPH0471484A
JPH0471484A JP2181487A JP18148790A JPH0471484A JP H0471484 A JPH0471484 A JP H0471484A JP 2181487 A JP2181487 A JP 2181487A JP 18148790 A JP18148790 A JP 18148790A JP H0471484 A JPH0471484 A JP H0471484A
Authority
JP
Japan
Prior art keywords
cells
culture
serum
bhk
aggregation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2181487A
Other languages
Japanese (ja)
Inventor
Miharu Takazawa
高沢 美治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Priority to JP2181487A priority Critical patent/JPH0471484A/en
Publication of JPH0471484A publication Critical patent/JPH0471484A/en
Pending legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PURPOSE:To obtain the subject cell, having a lower average aggregation degree of cells and a smaller number of the maximum aggregate cells than those of BHK cells, and capable of producing stable and useful substances according to suspension culture in an eRDF culture medium by acclimatizing the BHK cells to a serum-free culture medium and the suspension culture. CONSTITUTION:BHK cells are transferred from a serum culture medium to a serum-free culture medium, acclimatized for 1 month, then cultured in a suspen sion culture vessel having a structure, equipped with a settling zone divided with a partition wall on the inside of an outer wall and capable of feeding oxygen with a cellular Teflon(R) tube for 19 days and further cloned. Thereby, the BHK cells are acclimatized to the serum-free culture medium and further to the suspension culture. As a result, the objective low aggregating cells having an aggregation degree of cells of <=80% based on that of the BHK cells and the number of the maximum aggregate cells of <=10% based on that of the BHK cells are obtained.

Description

【発明の詳細な説明】 産業上の利用分野 本発明は低凝集性細胞及びこれを用いた培養方法に関す
るものである。更に詳しくは、サスペンション培養を行
なう際に培養を困難にする大きな凝集塊を形成しない細
胞及びこの細胞を用いてサスペンション培養を行なう方
法に関するものである。さらに該細胞を宿主と覆る遺伝
子導入方法に関する。
DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to low aggregation cells and culture methods using the same. More specifically, the present invention relates to cells that do not form large aggregates that make culture difficult during suspension culture, and a method for carrying out suspension culture using these cells. Furthermore, the present invention relates to a method for introducing a gene into the cell as a host.

従来技術 細胞の培養技術は、例えばウィルス、ワクブン。Conventional technology Examples of cell culture techniques include virus and Wakubun.

モノクロ−サル抗体、インターフエ日ンあるいはホルモ
ンなどの生理活性物質の製造にとって重要である。B 
HK細胞は従来古くからワクチン製造に用いられ、また
近年では効率の良い遺伝子導入宿主として重要性が高ま
っている。しかしBHK細胞は接着性細胞であるためマ
イクロキャリ曳7−やローラーボトルなどの何らかの接
着担体に接着させて培養するのが一般的である。このよ
うな担体を用いた培養はコストも高く、スケールアップ
にも適さない。このためB HK細胞のサスペンション
培養の試みもいくつかなされている(R,C。
It is important for the production of physiologically active substances such as monoclosal antibodies, interfering drugs, or hormones. B
HK cells have long been used for vaccine production, and in recent years have become increasingly important as efficient gene transfer hosts. However, since BHK cells are adherent cells, they are generally cultured by adhering to some kind of adhesive carrier such as a microcarrier or roller bottle. Culture using such carriers is costly and unsuitable for scale-up. For this reason, several attempts have been made to suspension culture BHK cells (R, C).

T ellino et al  B 1otechn
ol、B 1oeno、  7 。
T ellino et al B 1otechn
ol, B 1oeno, 7.

417(1965) : R,C,Te!!inget
 aB 1otechnol、31oena、9.25
7 (1967)  ; p 、3 。
417 (1965): R, C, Te! ! inget
aB 1otechnol, 31oena, 9.25
7 (1967); p, 3.

Capstick  Proc、Roy、  Soc、
  Med、  56. 1062(1963)  ;
 P、 J、 Radlett et at  App
l。
Capstick Proc, Roy, Soc,
Med, 56. 1062 (1963);
P. J. Radlett et at App.
l.

M 1crobiol、 22.534 (1971)
 ) 、しかしこれらの培養では細胞の大きな凝集は避
けられず、高密度化や長期培養に不向きであった。特に
無血清培地中では一般に血清培地中より細胞の凝集が大
きくなるためさらに培養が困難であった。
M 1crobiol, 22.534 (1971)
), however, large aggregation of cells was unavoidable in these cultures, making them unsuitable for high density and long-term culture. In particular, culturing was more difficult in a serum-free medium because cell aggregation was generally larger than in a serum medium.

また、通常用いられているBHK細胞は種々の特性を持
つヘテロな細胞群であると考えられる。
Furthermore, commonly used BHK cells are considered to be a heterogeneous cell group with various characteristics.

よってこれを遺伝子導入の親株として用いると、得られ
るクローンの培養特性は一定でなくサスペンション培養
に有利な低凝集クローンを得ることは極めて困難であっ
た。
Therefore, when this is used as a parent strain for gene introduction, the culture characteristics of the resulting clones are not constant, and it is extremely difficult to obtain low-aggregation clones that are advantageous for suspension culture.

発明の目的 そこで本発明者らは、BHKII細胞を細胞の凝集を抑
制してサスペンション培養を安定に行なうことを目的と
して研究を進めた。その結果B HK細胞をまず無血清
培地に馴化し、次にサスペンション培養に馴化し、さら
にクローニングを行なうことにより意外にももとのB 
HK株よりも凝集性の低いクローンが得られることを見
い出した。ここで、サスペンション培養とは水性媒体中
で細胞され自体が浮遊しながら生育されるような培養を
言う。
Purpose of the Invention Therefore, the present inventors conducted research with the aim of suppressing cell aggregation and stably culturing BHKII cells in suspension. As a result, by first acclimating BHK cells to serum-free medium, then acclimating them to suspension culture, and further cloning, we unexpectedly recovered the original BHK cells.
It has been found that clones with lower aggregation properties than the HK strain can be obtained. Here, suspension culture refers to a culture in which cells are grown while floating in an aqueous medium.

また、さらに意外なことにはこの低凝集株を遺伝子導入
宿主として用いると、遺伝子導入効率が大幅に増大覆る
ことを見い出した。よってこの低凝集性株を遺伝子導入
宿主として用いる場合、高い遺伝子導入効率で常に安定
な低凝集性遺伝子導入株を得ることができる。
Furthermore, it was surprisingly discovered that when this low-aggregation strain was used as a gene transfer host, the gene transfer efficiency was significantly increased. Therefore, when this low-agglutinating strain is used as a gene introduction host, a stable low-agglutinating gene-transferring strain can always be obtained with high gene transfer efficiency.

発明の椙成 りなわら本発明は、B HK’細胞を無血清培地に馴化
し、さらにサスペンション培養に馴化した細胞であって
、eRD F培地中でのサスペンション培養において細
胞の平均凝集度がBHK細胞の80%以下であり、かつ
最大凝集塊の細胞数がB l−I K細胞の最大凝集塊
の細胞数の10%以下である低凝集性細胞である。
At the dawn of the invention, the present invention provides BHK' cells adapted to a serum-free medium and further adapted to suspension culture, wherein the average degree of aggregation of the cells in suspension culture in eRDF medium is lower than that of BHK cells. and the number of cells in the maximum aggregate is 10% or less of the number of cells in the maximum aggregate of Bl-I K cells.

また、本発明は上記細胞を用いてサスペンション培養を
行なうことを特徴とする培養方法を包含する。また、本
弁明は上記細胞を宿主として用いることを特徴とする遺
伝子導入方法を包含する。
Furthermore, the present invention includes a culture method characterized by carrying out suspension culture using the above cells. Furthermore, the present defense includes a gene introduction method characterized by using the above cell as a host.

さらに具体的には、本発明はBHK細胞を無血清培地に
馴化し、さらにサスペンション培養に馴化した細胞であ
って、eRD F培地中に106cells /〆の密
度で懸濁した細胞懸濁液10ai!を50メ三角フラス
コ中で5%CO2,95%air雰囲気下188;’i
間37℃、 135rpiで旋回培養した際に、細胞の
平均凝集度が該BHK細胞の80%以下であり、かつ最
大凝集塊の大きさが100cells/塊以下あるいは
該B l−I K細胞の最大凝集塊の10%以下である
ような低凝集性細胞及びこれを用いてサスペンション培
養を行なうことを特徴とする培養方法である。
More specifically, the present invention provides a cell suspension of 10ai! cells which are BHK cells adapted to a serum-free medium and further adapted to suspension culture, suspended in eRD F medium at a density of 106 cells/〆! in a 50 m Erlenmeyer flask under an atmosphere of 5% CO2 and 95% air.
When cultured with rotation at 37°C and 135 rpm, the average degree of cell aggregation is 80% or less of the BHK cells, and the maximum aggregate size is 100 cells/clump or less, or the maximum of the Bl-I K cells. This culture method is characterized by carrying out suspension culture using low aggregation cells, which are less than 10% of the aggregates.

かかる本発明によれば、細胞の凝集を最少限に抑制して
細胞のサスペンション培養を安定に行うことが可能とな
る。
According to the present invention, it is possible to suppress cell aggregation to a minimum and stably perform suspension culture of cells.

以下本発明について詳細に説明する。The present invention will be explained in detail below.

本発明の低凝集性細胞はBHK507株より得られたも
のである。BHK507株とはBHK21株より得られ
た温度感受性株(ts13)  (T alavera
and Bacillico  J、 Ce1l Ph
ysiol、 92. 425436 (1977) 
)より分離されたチミジンキナーゼ欠損株(Waech
ter and Baserga、 PNAS  79
゜1106−1110(1982) )である。この細
胞を無血清サスペンション培養に馴化し、選択した。具
体的な馴化9選択方法は以下に示す通りである。
The low aggregation cells of the present invention are obtained from the BHK507 strain. BHK507 strain is a temperature-sensitive strain (ts13) obtained from BHK21 strain (T alavera
and Bacillico J, Ce1l Ph.
ysiol, 92. 425436 (1977)
) isolated from a thymidine kinase-deficient strain (Waech
ter and Baserga, PNAS 79
1106-1110 (1982)). The cells were adapted to serum-free suspension culture and selected. A specific method for selecting habituation 9 is as shown below.

まずBHKi8胞を自消含有培地から適当な無血清培地
(例えばI TES eRDト:  eRDF培地にイ
ンスリン9μg/lxf!、 トランスフェリン108
μg/d、エタノールアミン10μM、セレナイト20
 nMを添加したものなどが好ましい)に馴化する。手
順としては10%血清培地から直接無血清培地に細胞を
移して増殖して来るのを持っても良く、また血清含量を
段階的に減らしていっても良い。
First, transfer BHKi8 cells from a self-containing medium to an appropriate serum-free medium (for example, ITES eRD: eRDF medium containing insulin 9 μg/lxf!, transferrin 108).
μg/d, ethanolamine 10μM, selenite 20
(preferably those containing nM). As a procedure, cells may be directly transferred from a 10% serum medium to a serum-free medium and allowed to grow, or the serum content may be reduced stepwise.

適当な期間(好ましくは1か月収上)培養し、無血清培
地で増殖可能となったBHK細胞を次に同じ無血清培地
でサスペンションW18!培養する。潅流培養は新しい
培養液を培養槽中へ供給しつつ、古い培養液を培養槽外
へ排出しながら培養する方式である。培養装置はサスペ
ンション潅流培養に適したものならば何でも良い。培養
初期には細胞は大きな凝集塊を形成し、培養槽底部に沈
降してしまう。
BHK cells that have been cultured for an appropriate period (preferably one month) and can grow in a serum-free medium are then subjected to suspension W18! in the same serum-free medium. Cultivate. Perfusion culture is a method of culturing while supplying new culture solution into the culture tank and draining old culture solution out of the culture tank. Any culture device suitable for suspension perfusion culture may be used. At the early stage of culture, cells form large aggregates and settle to the bottom of the culture tank.

しかし培養を適当な期間継続していると(10日以上)
培養初期の凝集塊の数分の1以下の大きさの塊が出現し
てくる。これを無菌的に取り出し、適当なりローユング
法でクローニングする。得られたクローンの凝集性を比
較すると種々の異なるものが存在する。凝集性の測定法
としては適当容量(約50〜100aj ’)の三角フ
ラスコ中に適当密度の細胞懸濁液(106cells 
/Id!程度)を適当量(10〜20−)入れ、一定時
間(18〜24時間)振盪培養し、一定量の培地中の凝
集塊数を計数して平均凝集度を算出する(細胞懸濁液中
の全細胞数/凝集塊数)という方法が簡便かつ適切であ
るが、他の方法によっても良い。本発明で用いた条件は
以下に示す通りである。
However, if the culture is continued for an appropriate period (more than 10 days)
A lump smaller than a fraction of the size of the aggregate at the initial stage of culture appears. This is taken out aseptically and cloned using a suitable rowing method. Comparing the aggregation properties of the obtained clones, there are various different clones. To measure aggregation, a cell suspension of an appropriate density (106 cells) is placed in an Erlenmeyer flask with an appropriate volume (about 50 to 100 aj')
/Id! The average degree of aggregation is calculated by adding an appropriate amount (10 to 20 - Although the method (total number of cells/number of aggregates) is simple and appropriate, other methods may also be used. The conditions used in the present invention are as shown below.

■ 三角フラスコ容量 50Id ■ 細胞密度     106cells /d■ 培
地       ITESeRDF■ 細胞懸濁液容量
  10ate ■ 振盪機 大洋ロータリーシェーカー R−1■ 振
盪速度     135rpm ■ 温度       37℃ ■ 培養時間     18時間 ■ 雰囲気      5%CO2,95%air本条
件で各クローンの平均凝集度及び最大凝集塊の凝集度を
測定すると、例えば−例として以下のような値を示す。
■ Erlenmeyer flask capacity 50 Id ■ Cell density 106 cells / d ■ Medium ITESeRDF ■ Cell suspension capacity 10ate ■ Shaker Taiyo Rotary Shaker R-1 ■ Shaking speed 135 rpm ■ Temperature 37℃ ■ Culture time 18 hours ■ Atmosphere 5% CO2,95 %air When the average aggregation degree and the aggregation degree of the maximum aggregation of each clone are measured under these conditions, the following values are shown, for example.

(最大凝東度/馴化前のBl−IK細胞の最大凝集度)
×1■無血清、サスペンション培養に馴化前のBHK細
胞の同条件での平均凝集度は2.5、最大凝集度は50
6個/凝集塊)である。これより平均凝集度の小さいク
ローン、例えば上記■のようなりローンが本発明の対象
である。■あるいは■のような凝集度の高いクローンも
クローニングによって得られるが、これらはサスペンシ
ョン培養には適さない。
(Maximum coagulation degree/maximum aggregation degree of Bl-IK cells before acclimatization)
×1■ Serum-free, before acclimatization to suspension culture, the average aggregation degree of BHK cells under the same conditions is 2.5, and the maximum aggregation degree is 50.
6 pieces/agglomerate). Clones with a lower average aggregation degree than this, for example, clones like the one shown in (2) above, are the targets of the present invention. Clones with a high degree of aggregation such as ■ or ■ can also be obtained by cloning, but these are not suitable for suspension culture.

このようにして得られた無血清かスペンジジン培養馴化
細胞は有用物質の遺伝子導入の宿主細胞として、あるい
はワクヂン生産のためのウィルス産生宿主として有利に
用いることができるが、細胞の用途はこれらに限定され
るものではない。
The serum-free or spendidine culture-adapted cells thus obtained can be advantageously used as host cells for gene introduction of useful substances or as virus production hosts for vaccine production, but the uses of the cells are limited to these. It is not something that will be done.

リスペンション培養に用いる培養槽は細胞それ自体が液
体培地中に浮遊し撹拌されるものならばどのようなもの
でも良い。
Any type of culture tank may be used for resuspension culture as long as the cells themselves are suspended in a liquid medium and are stirred.

サスペンション培養に用いられる培養液は実質的に水よ
りなる水性媒体である。該水性媒体は動物I胞の培養に
通常使用される各種添加物例えば種々の無機塩、ビタミ
ン類、補酵素、ブドウ糖。
The culture medium used for suspension culture is an aqueous medium consisting essentially of water. The aqueous medium contains various additives commonly used in animal culture, such as various inorganic salts, vitamins, coenzymes, and glucose.

アミノ酸、抗生物質、増殖因子などを含有している。Contains amino acids, antibiotics, growth factors, etc.

また培養液には血清を加えることもできるが、血清を用
いないいわゆる無血清培地を用いることもできる。本発
明は殊に無血清培地に有利に適用される。
Further, although serum can be added to the culture solution, a so-called serum-free medium that does not use serum can also be used. The present invention is particularly advantageously applied to serum-free media.

かくして、本発明によれば細胞の凝集を最小限に抑えた
BHK細胞の安定した無血清サスペンション培養が可能
となる。また、潅流培養にも適している。
Thus, according to the present invention, stable serum-free suspension culture of BHK cells with minimal cell aggregation is possible. It is also suitable for perfusion culture.

発明の効果 本発明によれば、凝集度の小さい状態でサスペンション
培養を安定に行うことが可能となり有用物質の安定生産
が可能となった。さらに無血清培地で培養を行うことが
でき、潅流培養を行うことも可能となった。
Effects of the Invention According to the present invention, suspension culture can be carried out stably with a low degree of aggregation, and useful substances can be stably produced. Furthermore, it has become possible to perform culture in a serum-free medium, and it has also become possible to perform perfusion culture.

また、本発明の細胞によれば遺伝子導入の効率がBHK
I細胞にくらべ5〜40侶向上する。
Furthermore, according to the cells of the present invention, the efficiency of gene transfer is higher than that of BHK.
Improved by 5 to 40 cells compared to I cells.

実施例 以下に実施例を挙げ本発明を詳述する。Example The present invention will be explained in detail with reference to Examples below.

実施例1 低凝集BHK株の取得 (方法) 細!11:前述のB HK 507tk−株を用いた。Example 1 Obtaining low aggregation BHK strain (Method) Thin! 11: The aforementioned BHK 507tk- strain was used.

培養tI: 基礎培地として、RPM I 1640培地、ハムーF
12培地及びダルベツコ変法イーグル培地を2:1:1
で混合したものにアミノ酸、グルコース等をさらに増強
したもの(以下、e −RDFと称する)を用い、増殖
因子としてインスリン、トランスフェリン、エタノール
アミン、亜セレンM(ITES)を加えた。インスリン
の添加小は9μq/ld。
Culture tI: RPM I 1640 medium, Hamu F as basal medium
12 medium and Dulbecco's modified Eagle medium in a 2:1:1 ratio.
A mixture further enriched with amino acids, glucose, etc. (hereinafter referred to as e-RDF) was used, and insulin, transferrin, ethanolamine, and selenite M (ITES) were added as growth factors. The amount of insulin added was 9μq/ld.

トランスフェニリンは10μg/rd、エタノールアミ
ンは10μM、亜セレン酸は20 nMであった。
Transphenylin was 10 μg/rd, ethanolamine was 10 μM, and selenite was 20 nM.

まず、BHK 507tk−株を血清培地から上記無血
清培地ITES−eRDFに移し、1か月間馴化した。
First, the BHK 507tk- strain was transferred from the serum medium to the above serum-free medium ITES-eRDF and acclimatized for one month.

次にこの無血清培地馴化BHK 507tk−株をサス
ペンション培養槽で潅流培養した。
Next, this serum-free medium-acclimated BHK 507tk- strain was perfusion cultured in a suspension culture tank.

培養には添付第1図に示す培養システムを使用した。培
養槽は図のような外壁の内側に隔壁によって仕切られた
セトリングゾーンがもうけられ、その上部には培養液の
排出口を有しており、正味培養容積は約150af!で
あった。酸素は外径4III#Iφの多孔性テフロンチ
ューブによって供給した。
The culture system shown in the attached Figure 1 was used for culture. The culture tank has a settling zone partitioned by a partition wall inside the outer wall as shown in the figure, and has a culture solution outlet at the top, and the net culture volume is about 150 af! Met. Oxygen was supplied by a porous Teflon tube with an outer diameter of 4III#Iφ.

あらかじめオートクレーブ滅菌した前記培養槽に正味培
養容積が約150ai! 1.:なるように培養液を送
入し、これに無血清馴化B HK 507tk−株を1
、OX 106個/dとなるように播種した。培養槽に
は酸素ガスが(溶存酸素が3 ppmとなるように)吹
込みノズルを通して自動的にコントロールされた送入さ
れた。培養槽中の培養液は37℃に保持された。培養槽
中にはマリン型面1¥買が取付けられており、撹拌速度
は40rpm ”Cあった。
The net culture volume in the culture tank, which has been autoclaved in advance, is approximately 150 ai! 1. : Inject the culture medium so that the serum-free conditioned BHK 507tk- strain
, OX 106/d. Oxygen gas (3 ppm dissolved oxygen) was introduced into the culture tank in an automatically controlled manner through a blow nozzle. The culture solution in the culture tank was maintained at 37°C. A marine type surface was installed in the culture tank, and the stirring speed was 40 rpm.

播種後1日間は回分培養を行ない、この後パーヒコージ
〕ンを開始した。
Batch culture was carried out for one day after seeding, and then perhydration was started.

培養1日目から細胞は大きな凝集塊を形成し、培養槽底
部に数個の塊として沈降した。このまま還流培養を続け
たところ、培養2週間前後から小さな細胞塊が多数出現
し、サスペンション状態で増殖してきた。これを培養1
99日目無菌的に培養槽より取り出し、クローニングを
行なった。クロニングは以下の手順により行なった。
From the first day of culture, the cells formed large aggregates and settled in several clumps at the bottom of the culture tank. When reflux culture was continued as it was, many small cell clusters appeared after about 2 weeks of culture and began to proliferate in a suspension state. Culture this 1
On the 99th day, the cells were removed from the culture tank aseptically and cloning was performed. Cloning was performed according to the following procedure.

■ 細胞塊をトリプシン処理により個々の細胞に分離し
、eRD F中に1x103cells /dO)m度
で懸濁した。
■ The cell mass was separated into individual cells by trypsinization and suspended in eRDF at 1 x 103 cells/dO)m.

■ 96wellプレート1well当り1μ塁ずつ細
胞懸濁液を分注した。
(2) The cell suspension was dispensed into a 96-well plate in an amount of 1 μl per well.

■ 顕微鏡により1we++に1個の細胞が存在するw
ellを選び、40%FC8eRDF培地を1we当り
 100μ塁添加した。
■ Microscope shows that there is one cell in 1we++ lol
wells were selected, and 100 μl of 40% FC8eRDF medium was added to each well.

■ 約2週間後、増殖してきた細胞をデイツシユに移し
、十分な細胞数が得られたところで凝集度を測定した。
■ After about 2 weeks, the proliferated cells were transferred to a dish, and when a sufficient number of cells was obtained, the degree of aggregation was measured.

凝集度は本文記載の方法により測定した。The degree of aggregation was measured by the method described in the text.

(結果) 得られた4クローンのBHK株の平均凝集度及び最大凝
集度を第1表に示す。
(Results) Table 1 shows the average aggregation degree and maximum aggregation degree of the BHK strain of the four clones obtained.

第1表(実施例1実験結果) 未馴化B HK 507tk−株の平均凝集度、最大凝
集度はそれぞれ2.5. 506個/凝集塊であった。
Table 1 (Example 1 Experimental Results) The average aggregation degree and maximum aggregation degree of the unacclimated BHK 507tk- strain were 2.5. The number was 506 pieces/aggregate.

最も凝集度の低かった12D株を以下の実施例に用い 
Iこ 。
The 12D strain, which had the lowest degree of aggregation, was used in the following examples.
I.

実施例1記載株サスペンション培養 (方法) 細胞に実施例1記載の低凝集株12D株を用いた以外は
実施例1のサスペンション培養と同様に行なった。培養
は12日間継続した。結果を第2表に示す。
Suspension culture of the strain described in Example 1 (method) Suspension culture was carried out in the same manner as in Example 1 except that the low aggregation strain 12D strain described in Example 1 was used as the cell. Culture continued for 12 days. The results are shown in Table 2.

第2表 実施例2実験結果 細胞  12[)株 培地 ITESeR[)F 比較例1 細胞にサスペンション培養馴化1遺択を行なっていない
無血清馴化B HK 507tk−株を用いた以外は実
施例2と同様に行なった。培養は5日間継続した。結果
を第3表に示す。
Table 2 Example 2 Experimental Results Cells 12[) strain culture medium ITESeR[)F Comparative Example 1 Same as Example 2 except that serum-free conditioned BHK 507tk- strain without suspension culture conditioning 1 was used for the cells. I did the same. Culture continued for 5 days. The results are shown in Table 3.

第3表 比較例実験結果 細胞  無血清馴化8HK 507tk−株培地 ITES cRDF ※ 細胞の凝集が大きいため培養途中の4ノンブリング
が不可能であった。
Table 3 Comparative Example Experimental Results Cells Serum-free conditioned 8HK 507tk-strain medium ITES cRDF *Due to large cell aggregation, it was impossible to carry out non-bringing during culture.

実施例312D株への遺伝子導入 (方法) 細胞:12D株 導入遺伝子:ヒトプロティンCC−DNA及びジヒドロ
葉酸還元酵素(dMr)遺伝子を持つプラスミド 遺伝子導入方法二通常のカルシウム−リン酸法によった
Example 3 Gene introduction into 12D strain (method) Cells: 12D strain Transgene: Plasmid with human protein CC-DNA and dihydrofolate reductase (dMr) gene Gene introduction method 2 A conventional calcium-phosphate method was used.

10αφのプラスチックデイツシュ上で増殖するB )
−I K 12D株約5 x 106cells ニリ
ン酸カルシウムに共沈させた上記遺伝子10μ9を加え
、6時間静置の後10%FC8eRDFに培地を交換し
、2日問培養した。2日後メソトレキセート((+)A
METHOPTERIN、S+ua)1μMを含む5%
透析FC8OME培地に移し、安定形質転換株(sta
ble transforlant )を選択した。
B) growing on 10αφ plastic dates
-I K 12D strain approximately 5 x 106 cells 10μ9 of the above gene coprecipitated with calcium diphosphate was added, and after standing for 6 hours, the medium was changed to 10% FC8eRDF and cultured for 2 days. 2 days later methotrexate ((+)A
METHOPTERIN, S+ua) 5% containing 1 μM
Transfer to dialyzed FC8OME medium to transform stable transformants (sta
ble transform) was selected.

この際の培養にはisc、φプラスチックデイツシュを
用い、培地間は30〆/デイツシユとした。
At this time, ISC and φ plastic dishes were used for the culture, and the distance between the media was set at 30 times/dish.

約2週間後生育してきたコロニー数を計数し、遺伝子導
入効率を求めた。
After about 2 weeks, the number of colonies that had grown was counted to determine the gene transfer efficiency.

(結果) 遺伝子導入効率を第4表に示す。(result) The gene transfer efficiency is shown in Table 4.

第4表 12[)株への遺伝子導入効率本カウント不能
(コロニー数多数のため)得られたコロニーはほぼすべ
てPC産生細胞であった。最大PC産生クローンのPC
産生濃度は2.4μ9/rdであった。
Table 4 Efficiency of gene introduction into strain 12[) Almost all colonies obtained were unable to be counted (due to large number of colonies) and were PC-producing cells. PC of maximum PC producing clone
The production concentration was 2.4μ9/rd.

比較例2  Bl−(K 507tk−株への遺伝子導
入(方法) 細胞に無血清、サスペンション未馴化BHK507tk
−を用いた以外は実施例3と同様に行なった。
Comparative Example 2 Gene introduction into Bl-(K 507tk- strain (method) Cells were serum-free and suspension-unacclimated BHK507tk
The same procedure as in Example 3 was carried out except that - was used.

(結果) 遺伝子導入効率を第5表に示す。(result) The gene transfer efficiency is shown in Table 5.

第1図 第5表 [3l−IK 507tk−株への遺伝子導入
効率得られたコロニーはほぼすべてPC産生細胞であっ
た。最大PC産生クローンのPC産生濃度は2.4μ9
/ldであった。
Figure 1, Table 5 [Efficiency of gene introduction into 3l-IK 507tk- strain] Almost all of the colonies obtained were PC-producing cells. The PC production concentration of the maximum PC producing clone is 2.4 μ9
/ld.

【図面の簡単な説明】[Brief explanation of the drawing]

第1図は実施例において使用した培養システムの概略図
を示す。 使用済培地
FIG. 1 shows a schematic diagram of the culture system used in the examples. used medium

Claims (3)

【特許請求の範囲】[Claims] (1)BHK細胞を無血清培地に馴化し、さらにサスペ
ンション培養に馴化した細胞であって、eRDF培地中
でのサスペンション培養において細胞の平均凝集度がB
HK細胞の80%以下であり、かつ最大凝集塊の細胞数
がBHK細胞の最大凝集塊の細胞数の10%以下である
低凝集性細胞。
(1) BHK cells are acclimatized to serum-free medium and further adapted to suspension culture, and the average degree of cell aggregation is B in suspension culture in eRDF medium.
Low aggregation cells that are 80% or less of HK cells, and the number of cells in the maximum aggregate is 10% or less of the number of cells in the maximum aggregate of BHK cells.
(2)請求項1記載の細胞を用いてサスペンション培養
を行なうことを特徴とする培養方法。
(2) A culture method comprising carrying out suspension culture using the cells according to claim 1.
(3)請求項1記載の細胞を宿主として用いることを特
徴とする遺伝子導入方法。
(3) A method for gene introduction, which comprises using the cell according to claim 1 as a host.
JP2181487A 1990-07-11 1990-07-11 Low aggregating cell and method for culturing the same Pending JPH0471484A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2181487A JPH0471484A (en) 1990-07-11 1990-07-11 Low aggregating cell and method for culturing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2181487A JPH0471484A (en) 1990-07-11 1990-07-11 Low aggregating cell and method for culturing the same

Publications (1)

Publication Number Publication Date
JPH0471484A true JPH0471484A (en) 1992-03-06

Family

ID=16101622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2181487A Pending JPH0471484A (en) 1990-07-11 1990-07-11 Low aggregating cell and method for culturing the same

Country Status (1)

Country Link
JP (1) JPH0471484A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5535901A (en) * 1993-05-17 1996-07-16 Yoshino Kogyosho Co., Ltd. Synthetic resin bottle with handle and its production method
JP2009502167A (en) * 2005-07-25 2009-01-29 イムノメディクス, インコーポレイテッド Improved methods and compositions for extending cell culture life and increasing protein yield from cultured cells
JP2012254084A (en) * 2004-07-23 2012-12-27 Immunomedics Inc Method and composition for increasing longevity and originated protein yield of cell culture

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5535901A (en) * 1993-05-17 1996-07-16 Yoshino Kogyosho Co., Ltd. Synthetic resin bottle with handle and its production method
JP2012254084A (en) * 2004-07-23 2012-12-27 Immunomedics Inc Method and composition for increasing longevity and originated protein yield of cell culture
JP2009502167A (en) * 2005-07-25 2009-01-29 イムノメディクス, インコーポレイテッド Improved methods and compositions for extending cell culture life and increasing protein yield from cultured cells

Similar Documents

Publication Publication Date Title
Schimmer [52] Adrenocortical Y1 cells
JP2577114B2 (en) Cell culture media
US6194210B1 (en) Hepatitis A virus culture process
Reuveny Microcarrier culture systems
US20080009064A1 (en) Temperature-Responsive Microcarrier
Butler Growth limitations in microcarrier cultures
JPH08508875A (en) Fed-batch culture of protein-secreting cells
JPH0471484A (en) Low aggregating cell and method for culturing the same
Jakob et al. [6] Mouse teratocarcinoma cells
JP4478328B2 (en) Preparation of cells for biochemical drug production
JP2859679B2 (en) New cell line
CN109402040A (en) Suitable serum-free suspends the bhk cell and its acclimation method of culture entirely
JPH0416153B2 (en)
JPS62181780A (en) Cultivation of animal cell
Nayve Jr et al. HBs-MAb production in perfusion culture with selective ammonia removal system
Varani et al. Human diploid fibroblast growth on polystyrene microcarriers in aggregates
JPH04360677A (en) Suspended cell culture process
JPH0375154B2 (en)
JPH01296984A (en) Culture of adherent animal cell
JPH07135968A (en) Adhesion of adhesion-independent cell to microcarrier
JPH05252944A (en) Tissue culture process
JPH0398572A (en) Cell culture device and cell culture
JPS63209582A (en) Cultivation of attaching animal cell
CN111534478A (en) Culture medium for culturing MDCK cell line and preparation method thereof
JPS59146598A (en) Production of interferon